Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 7, 2012; 18(21): 2600-2608
Published online Jun 7, 2012. doi: 10.3748/wjg.v18.i21.2600
Published online Jun 7, 2012. doi: 10.3748/wjg.v18.i21.2600
FDA category | Definition |
A | Controlled studies in animals and women have shown no risk in the first trimester, and possible foetal harm is remote |
B | Either animal studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women, or animal studies have shown an adverse effect that was not confirmed in controlled studies in women in the first trimester |
C | No controlled studies in humans have been performed, and animal studies have shown adverse events, or studies in humans and animals not available; give if potential benefit outweighs the risk |
D | Positive evidence of foetal risk is available, but the benefits may outweigh the risk if life-threatening or serious disease |
X | Studies in animals or humans show foetal abnormalities; drug contraindicated |
- Citation: Selinger CP, Leong RW, Lal S. Pregnancy related issues in inflammatory bowel disease: Evidence base and patients' perspective. World J Gastroenterol 2012; 18(21): 2600-2608
- URL: https://www.wjgnet.com/1007-9327/full/v18/i21/2600.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i21.2600